Latest News
uniQure reports initial six‑month data from first AMT‑260 dose cohort
19 June 2026 - Dutch-American gene therapy company uniQure N.V. (NASDAQ: QURE) on Friday released initial six-month follow-up data from the first, low-dose cohort in its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy, cover...
Incyte Japan wins approval for Minjuvi combination therapy in relapsed or refractory DLBCL
19 June 2026 - Incyte Biosciences Japan G.K., part of global biopharmaceutical company Incyte (Nasdaq:INCY), announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidom...
Teijin and Merz secure Japanese approval for additional XEOMIN indications
19 June 2026 - Teijin Pharma Limited, part of Japanese technology holding company Teijin Group (TSE:3401), and Merz Therapeutics GmbH, part of Germany's Merz Group, announced on Friday that Japan's Ministry of Health, Labour and Welfare has...
Silo Pharma regains compliance with Nasdaq minimum bid price
19 June 2026 - Silo Pharma (Nasdaq:SILO), a developmental-stage biopharmaceutical company involved in novel therapeutics and drug delivery systems, announced on Thursday that it has received confirmation that it has regained compliance with the minim...
Alvotech raises USD165m in public offering and private placement
19 June 2026 - Biotechnology company Alvotech (NASDAQ:ALVO) announced on Thursday the closing of its underwritten public offering of 26,066,667 of its ordinary shares at an offering price of USD3.75 per share, which includes 3,400,000 ordinary shares...